Synergizing genome editing and cancer immunotherapy

Cancer immunotherapy has recently become a powerful treatment option as several strategies harnessing the immune system to fight cancer achieved remarkable therapeutic benefits in clinical trials. Oncolytic viruses mediate selective tumor cell lysis (1), checkpoint inhibitors block receptors such as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gabriel, Richard (VerfasserIn) , Knipping, Friederike (VerfasserIn) , Kalle, Christof von (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: May 23, 2017
In: Translational cancer research
Year: 2017, Jahrgang: 6, Pages: S969-S972
ISSN:2219-6803
DOI:10.21037/tcr.2017.06.11
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.21037/tcr.2017.06.11
Verlag, kostenfrei, Volltext: http://tcr.amegroups.com/article/view/13967
Volltext
Verfasserangaben:Richard Gabriel, Friederike Knipping, Christof von Kalle

MARC

LEADER 00000caa a2200000 c 4500
001 1576027880
003 DE-627
005 20220814153720.0
007 cr uuu---uuuuu
008 180606s2017 xx |||||o 00| ||eng c
024 7 |a 10.21037/tcr.2017.06.11  |2 doi 
035 |a (DE-627)1576027880 
035 |a (DE-576)506027880 
035 |a (DE-599)BSZ506027880 
035 |a (OCoLC)1341011076 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Gabriel, Richard  |e VerfasserIn  |0 (DE-588)1017959846  |0 (DE-627)690473427  |0 (DE-576)354092332  |4 aut 
245 1 0 |a Synergizing genome editing and cancer immunotherapy  |c Richard Gabriel, Friederike Knipping, Christof von Kalle 
264 1 |c May 23, 2017 
300 |a 4 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.06.2018 
520 |a Cancer immunotherapy has recently become a powerful treatment option as several strategies harnessing the immune system to fight cancer achieved remarkable therapeutic benefits in clinical trials. Oncolytic viruses mediate selective tumor cell lysis (1), checkpoint inhibitors block receptors such as CTLA4 or PD1 on T cells and/or their ligands on tumor cells to reverse T cell suppression (2) and adoptive T cell therapy uses autologous tumor infiltrating lymphocytes (TIL) or genetically modified T cells to kill cancer cells. The latter has recently led to unprecedented efficacy, predominantly as a treatment for melanoma and leukemia. Similarly, gene editing—the precise modification of genes and genomic loci—holds enormous potential for clinical and research applications, primarily owing to the ease of use of the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPRassociated (Cas9) system that has transformed gene editing into a widely-used technique (3). Research efforts in both fields are currently combined by exploiting gene editing to enhance efficacy and safety of adoptive T cell therapies. In a recent edition of Nature, Eyquem and colleagues showed the superior potency of gene edited T cells in eliminating tumor cells and promoting survival (4). 
700 1 |a Knipping, Friederike  |e VerfasserIn  |0 (DE-588)1139071866  |0 (DE-627)896672751  |0 (DE-576)492913315  |4 aut 
700 1 |a Kalle, Christof von  |d 1962-  |e VerfasserIn  |0 (DE-588)1036481115  |0 (DE-627)75107926X  |0 (DE-576)168957396  |4 aut 
773 0 8 |i Enthalten in  |t Translational cancer research  |d Shatin : AME Publishing Company, 2012  |g 6(2017), Supplement 6, Seite S969-S972  |h Online-Ressource  |w (DE-627)894990276  |w (DE-600)2901601-0  |w (DE-576)491668899  |x 2219-6803  |7 nnas  |a Synergizing genome editing and cancer immunotherapy 
773 1 8 |g volume:6  |g year:2017  |g supplement:Supplement 6  |g pages:S969-S972  |g extent:4  |a Synergizing genome editing and cancer immunotherapy 
856 4 0 |u http://dx.doi.org/10.21037/tcr.2017.06.11  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://tcr.amegroups.com/article/view/13967  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180606 
993 |a Article 
994 |a 2017 
998 |g 1036481115  |a Kalle, Christof von  |m 1036481115:Kalle, Christof von  |d 910000  |e 910000PK1036481115  |k 0/910000/  |p 3  |y j 
998 |g 1139071866  |a Knipping, Friederike  |m 1139071866:Knipping, Friederike  |d 910000  |e 910000PK1139071866  |k 0/910000/  |p 2 
998 |g 1017959846  |a Gabriel, Richard  |m 1017959846:Gabriel, Richard  |d 140000  |e 140000PG1017959846  |k 0/140000/  |p 1  |x j 
999 |a KXP-PPN1576027880  |e 3011670935 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"title":[{"subtitle":"TCR","title":"Translational cancer research","title_sort":"Translational cancer research"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Transl Cancer Res TCR"},{"title":"TCR"}],"pubHistory":["Vol 1, no 1 (June 2012)-"],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["894990276"],"zdb":["2901601-0"],"issn":["2219-6803"]},"origin":[{"publisher":"AME Publishing Company","dateIssuedDisp":"[2012]-","publisherPlace":"Shatin"}],"part":{"extent":"4","text":"6(2017), Supplement 6, Seite S969-S972","pages":"S969-S972","volume":"6","year":"2017"},"recId":"894990276","disp":"Synergizing genome editing and cancer immunotherapyTranslational cancer research"}],"note":["Gesehen am 06.06.2018"],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"May 23, 2017"}],"id":{"eki":["1576027880"],"doi":["10.21037/tcr.2017.06.11"]},"recId":"1576027880","name":{"displayForm":["Richard Gabriel, Friederike Knipping, Christof von Kalle"]},"title":[{"title_sort":"Synergizing genome editing and cancer immunotherapy","title":"Synergizing genome editing and cancer immunotherapy"}],"person":[{"family":"Gabriel","given":"Richard","role":"aut","display":"Gabriel, Richard"},{"display":"Knipping, Friederike","role":"aut","given":"Friederike","family":"Knipping"},{"display":"Kalle, Christof von","family":"Kalle","given":"Christof von","role":"aut"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"4 S."}],"language":["eng"]} 
SRT |a GABRIELRICSYNERGIZIN2320